Literature DB >> 22163141

Valvular heart disease with the use of fenfluramine-phentermine.

Phani Surapaneni1, Karyne L Vinales, Mohammad Q Najib, Hari P Chaliki.   

Abstract

Exposure to the anorectic drug fenfluramine, alone or in combination with phentermine, a noradrenergic central nervous system stimulant, has been associated with unusual cardiac valvular morphology and resultant regurgitation of the left- and right-sided heart valves. The prevalence of significant valvular disease associated with the use of these anorectic drugs is reported to be as high as 23%. Herein, we report the occurrence of multivalvular disease and pulmonary hypertension associated with fenfluramine-phentermine use, discovered in an obese 59-year-old woman before expected gastric bypass surgery.

Entities:  

Keywords:  Aortic valve insufficiency/chemically induced; appetite depressants/adverse effects; fenfluramine/adverse effects; heart valve diseases/chemically induced/complications/pathology; hypertension, pulmonary/chemically induced; mitral valve insufficiency/chemically induced; obesity/complications; phentermine/adverse effects; treatment outcome; tricuspid valve insufficiency/chemically induced

Mesh:

Substances:

Year:  2011        PMID: 22163141      PMCID: PMC3231534     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  6 in total

1.  Valvular heart disease associated with fenfluramine-phentermine.

Authors:  H M Connolly; J L Crary; M D McGoon; D D Hensrud; B S Edwards; W D Edwards; H V Schaff
Journal:  N Engl J Med       Date:  1997-08-28       Impact factor: 91.245

2.  ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.

Authors:  Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel
Journal:  J Am Coll Cardiol       Date:  2006-08-01       Impact factor: 24.094

3.  The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.

Authors:  M A Khan; C A Herzog; J V St Peter; G G Hartley; R Madlon-Kay; C D Dick; R W Asinger; J T Vessey
Journal:  N Engl J Med       Date:  1998-09-10       Impact factor: 91.245

4.  The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.

Authors:  S T Mast; J G Jollis; T Ryan; K J Anstrom; J L Crary
Journal:  Ann Intern Med       Date:  2001-02-20       Impact factor: 25.391

5.  Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.

Authors:  P A Pellikka; A J Tajik; B K Khandheria; J B Seward; J A Callahan; H C Pitot; L K Kvols
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

6.  Primary pulmonary hypertension and fenfluramine use.

Authors:  F Brenot; P Herve; P Petitpretz; F Parent; P Duroux; G Simonneau
Journal:  Br Heart J       Date:  1993-12
  6 in total
  1 in total

1.  Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.

Authors:  Paul N Black; Constance Ahowesso; David Montefusco; Nipun Saini; Concetta C DiRusso
Journal:  Medchemcomm       Date:  2016-02-19       Impact factor: 3.597

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.